RxDoctor Payments Data

Jayalekshmy Kumar, MD

Neurology · Hopedale, MANPI 1184658825

Payments from drug & device makers

$23,383in general payments, 2019–2025

Across 1,216 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Pfizer$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • Lundbeck LLC$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$1761%
  • Food & beverage$22,82698%
  • Education$3812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)158$2,865
Teva Pharmaceuticals USA, Inc.88$1,431
Pfizer89$1,419
Novartis86$1,359
UCB, Inc.75$1,353
Lundbeck LLC46$1,001
Biogen46$948
Eisai Inc.51$944
Amneal Pharmaceuticals LLC44$846
EMD Serono, Inc.26$756
CSL Behring30$734
SK Life Science, Inc.27$688
Sunovion Pharmaceuticals Inc.40$616
Lilly USA, LLC36$594
Sanofi22$509
AstraZeneca(2 entities)21$506
Biohaven Pharmaceutical Holding Company Ltd.42$445
Amgen(2 entities)16$434
Supernus Pharmaceuticals, Inc.12$403
Merz Pharmaceuticals, LLC13$368
ANI Pharmaceuticals, Inc.14$353
Johnson & Johnson(2 entities)16$330
MDD US Operations, LLC14$275
Genentech USA, Inc.13$266
Mallinckrodt Enterprises LLC12$255
Bristol Myers Squibb10$236
Kyowa Kirin, Inc.10$214
Argenx US, Inc.11$210
Mallinckrodt Hospital Products Inc.7$205
Acorda Therapeutics, Inc10$202
Neurocrine Biosciences, Inc.11$197
Impel Pharmaceuticals Inc.14$188
Neurelis, Inc.8$169
Catalyst Pharmaceuticals, Inc.8$167
Tanabe Pharma America, Inc.6$127
Otsuka America Pharmaceutical, Inc.5$115
Acadia Pharmaceuticals Inc5$90
Adamas Pharmaceuticals, Inc.4$89
Harmony Biosciences LLC2$89
Upsher-smith Laboratories LLC5$86
Grifols USA, LLC4$83
Takeda Pharmaceuticals U.S.A., Inc.3$81
Assertio Therapeutics, Inc.4$80
Inspire Medical Systems, Inc.4$78
Livanova USA, Inc.4$76
Alnylam Pharmaceuticals Inc.3$71
Biohaven Pharmaceuticals, Inc.3$71
Vanda Pharmaceuticals Inc.3$70
GE HealthCare4$68
Idorsia Pharmaceuticals US Inc3$63
Almatica Pharma LLC2$61
TG Therapeutics, Inc.3$60
Zyla Life Sciences, Inc.4$55
Balt USA, LLC1$48
Life Molecular Imaging Ltd2$43
Arbor Pharmaceuticals, Inc.2$37
Avanir Pharmaceuticals, Inc.2$34
Axsome Therapeutics, Inc.2$31
Greenwich Biosciences, Inc.1$25
E.r. Squibb & Sons, L.L.C.1$24

How this compares

$23,383 in reported general payments places this provider in the 70th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$152,679
Medicare patients
302
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5034$298,116
IngrezzaValbenazine Tosylate11$163,982
AustedoDeutetrabenazine15$154,112
Nurtec OdtRimegepant Sulfate42$71,996
NeuproRotigotine53$54,087
Dimethyl Fumarate11$49,433
Emgality PenGalcanezumab-Gnlm59$40,863
BriviactBrivaracetam13$34,376
UbrelvyUbrogepant23$32,915
RytaryCarbidopa/Levodopa18$29,769
Aimovig AutoinjectorErenumab-Aooe25$18,650
BotoxOnabotulinumtoxina14$18,179
QuliptaAtogepant14$17,064
OngentysOpicapone20$14,493
Lacosamide97$11,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$81$298,11634 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$197$178,47431 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,431$154,11215 claims
UCB, Inc.Neupro, Briviact$1,353$88,46366 claims
PfizerNurtec Odt$1,419$71,99642 claims
AbbVieUbrelvy, Botox, Qulipta$2,865$68,15751 claims
Amneal Pharmaceuticals LLCRytary$846$29,76918 claims
Upsher-smith Laboratories LLCTopiramate$86$1,89099 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 761 neurology providers in Massachusetts.

Other neurology in Hopedale

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →